151 related articles for article (PubMed ID: 17918921)
1. Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
Altenbach RJ; Liu H; Banfor PN; Browman KE; Fox GB; Fryer RM; Komater VA; Krueger KM; Marsh K; Miller TR; Pan JB; Pan L; Sun M; Thiffault C; Wetter J; Zhao C; Zhou D; Esbenshade TA; Hancock AA; Cowart MD
J Med Chem; 2007 Nov; 50(22):5439-48. PubMed ID: 17918921
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
[TBL] [Abstract][Full Text] [Related]
3. Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H₃ receptor antagonists with potent cognition enhancing activity.
Tao M; Aimone LD; Huang Z; Mathiasen J; Raddatz R; Lyons J; Hudkins RL
J Med Chem; 2012 Jan; 55(1):414-23. PubMed ID: 22107017
[TBL] [Abstract][Full Text] [Related]
4. In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.
Hancock AA; Diehl MS; Faghih R; Bush EN; Krueger KM; Krishna G; Miller TR; Wilcox DM; Nguyen P; Pratt JK; Cowart MD; Esbenshade TA; Jacobson PB
Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):144-52. PubMed ID: 15447739
[TBL] [Abstract][Full Text] [Related]
5. Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity.
Cowart M; Gfesser GA; Browman KE; Faghih R; Miller TR; Milicic I; Baranowski JL; Krueger KM; Witte DG; Molesky AL; Komater VA; Buckley MJ; Diaz GJ; Gagne GD; Zhou D; Deng X; Pan L; Roberts EM; Diehl MS; Wetter JM; Marsh KC; Fox GB; Brioni JD; Esbenshade TA; Hancock AA
Biochem Pharmacol; 2007 Apr; 73(8):1243-55. PubMed ID: 17371699
[TBL] [Abstract][Full Text] [Related]
6. The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
Zhao C; Sun M; Bennani YL; Gopalakrishnan SM; Witte DG; Miller TR; Krueger KM; Browman KE; Thiffault C; Wetter J; Marsh KC; Hancock AA; Esbenshade TA; Cowart MD
J Med Chem; 2008 Sep; 51(17):5423-30. PubMed ID: 18683917
[TBL] [Abstract][Full Text] [Related]
7. 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
Cowart M; Faghih R; Curtis MP; Gfesser GA; Bennani YL; Black LA; Pan L; Marsh KC; Sullivan JP; Esbenshade TA; Fox GB; Hancock AA
J Med Chem; 2005 Jan; 48(1):38-55. PubMed ID: 15634000
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.
Pastorin G; Da Ros T; Bolcato C; Montopoli C; Moro S; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
J Med Chem; 2006 Mar; 49(5):1720-9. PubMed ID: 16509587
[TBL] [Abstract][Full Text] [Related]
9. 4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
Black LA; Nersesian DL; Sharma P; Ku YY; Bennani YL; Marsh KC; Miller TR; Esbenshade TA; Hancock AA; Cowart M
Bioorg Med Chem Lett; 2007 Mar; 17(5):1443-6. PubMed ID: 17169555
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist.
Esbenshade TA; Browman KE; Miller TR; Krueger KM; Komater-Roderwald V; Zhang M; Fox GB; Rueter L; Robb HM; Radek RJ; Drescher KU; Fey TA; Bitner RS; Marsh K; Polakowski JS; Zhao C; Cowart MD; Hancock AA; Sullivan JP; Brioni JD
J Pharmacol Exp Ther; 2012 Oct; 343(1):233-45. PubMed ID: 22815533
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and in vivo evaluation of phenethylpiperazine amides: selective 5-hydroxytryptamine(2A) receptor antagonists for the treatment of insomnia.
Xiong Y; Ullman B; Choi JS; Cherrier M; Strah-Pleynet S; Decaire M; Dosa PI; Feichtinger K; Teegarden BR; Frazer JM; Yoon WH; Shan Y; Whelan K; Hauser EK; Grottick AJ; Semple G; Al-Shamma H
J Med Chem; 2010 Aug; 53(15):5696-706. PubMed ID: 20684606
[TBL] [Abstract][Full Text] [Related]
12. 4-benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists.
Wijtmans M; Celanire S; Snip E; Gillard MR; Gelens E; Collart PP; Venhuis BJ; Christophe B; Hulscher S; van der Goot H; Lebon F; Timmerman H; Bakker RA; Lallemand BI; Leurs R; Talaga PE; de Esch IJ
J Med Chem; 2008 May; 51(10):2944-53. PubMed ID: 18433114
[TBL] [Abstract][Full Text] [Related]
13. 2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists.
Zaragoza F; Stephensen H; Peschke B; Rimvall K
J Med Chem; 2005 Jan; 48(1):306-11. PubMed ID: 15634025
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, structure-activity relationship, and receptor pharmacology of a new series of quinoline derivatives acting as selective, noncompetitive mGlu1 antagonists.
Mabire D; Coupa S; Adelinet C; Poncelet A; Simonnet Y; Venet M; Wouters R; Lesage AS; Van Beijsterveldt L; Bischoff F
J Med Chem; 2005 Mar; 48(6):2134-53. PubMed ID: 15771457
[TBL] [Abstract][Full Text] [Related]
15. Selective naphthalene H(3) receptor inverse agonists with reduced potential to induce phospholipidosis and their quinoline analogs.
Rodríguez Sarmiento RM; Nettekoven MH; Taylor S; Plancher JM; Richter H; Roche O
Bioorg Med Chem Lett; 2009 Aug; 19(15):4495-500. PubMed ID: 19524437
[TBL] [Abstract][Full Text] [Related]
16. Heterocyclic replacement of the central phenyl core of diamine-based histamine H3 receptor antagonists.
Swanson DM; Shah CR; Lord B; Morton K; Dvorak LK; Mazur C; Apodaca R; Xiao W; Boggs JD; Feinstein M; Wilson SJ; Barbier AJ; Bonaventure P; Lovenberg TW; Carruthers NI
Eur J Med Chem; 2009 Nov; 44(11):4413-25. PubMed ID: 19577344
[TBL] [Abstract][Full Text] [Related]
17. Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization.
Fox GB; Pan JB; Radek RJ; Lewis AM; Bitner RS; Esbenshade TA; Faghih R; Bennani YL; Williams M; Yao BB; Decker MW; Hancock AA
J Pharmacol Exp Ther; 2003 Jun; 305(3):897-908. PubMed ID: 12606600
[TBL] [Abstract][Full Text] [Related]
18. Fluorinated non-imidazole histamine H3 receptor antagonists.
Isensee K; Amon M; Garlapati A; Ligneau X; Camelin JC; Capet M; Schwartz JC; Stark H
Bioorg Med Chem Lett; 2009 Apr; 19(8):2172-5. PubMed ID: 19286376
[TBL] [Abstract][Full Text] [Related]
19. Structure-guided optimization of estrogen receptor binding affinity and antagonist potency of pyrazolopyrimidines with basic side chains.
Zhou HB; Sheng S; Compton DR; Kim Y; Joachimiak A; Sharma S; Carlson KE; Katzenellenbogen BS; Nettles KW; Greene GL; Katzenellenbogen JA
J Med Chem; 2007 Jan; 50(2):399-403. PubMed ID: 17228884
[TBL] [Abstract][Full Text] [Related]
20. DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization.
James ML; Fulton RR; Vercoullie J; Henderson DJ; Garreau L; Chalon S; Dolle F; Costa B; Guilloteau D; Kassiou M
J Nucl Med; 2008 May; 49(5):814-22. PubMed ID: 18413395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
